Alborz Zagros, a member of Actoverco Pharmaceutical Group, has introduced Upavoq (Upadacitinib), an oral selective Janus Kinase (JAK) inhibitor, to the Iranian pharmaceutical market. Available in 15 mg, 30 mg, and 45 mg strengths, the medication is indicated for the treatment of several inflammatory and autoimmune conditions across rheumatology, dermatology, and gastroenterology, in accordance with approved indications.
Alborz Zagros, a member of Actover Pharmaceutical Group, has introduced Upavoq, an oral medication containing Upadacitinib, to the Iranian pharmaceutical market. The drug is a targeted therapy designed to treat certain inflammatory diseases.
According to the Public Relations Department of Actoverco Pharmaceutical Group, Upadacitinib belongs to the class of selective (JAK) inhibitors. By inhibiting signaling pathways involved in inflammatory processes, it is used to treat certain inflammatory and autoimmune conditions.
The therapeutic applications of Upadacitinib extend across several medical specialties, including rheumatology, dermatology, and gastroenterology.
Based on its approved indications, Upadacitinib is used in the treatment of eligible patients with conditions including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, vitiligo, alopecia areata, Crohn’s disease, and ulcerative colitis.
Upavoq is available in 15 mg, 30 mg, and 45 mg strengths. Its introduction aims to improve access for healthcare professionals and eligible patients to an evidence-based oral treatment option, with an emphasis on compliance with manufacturing and quality control requirements.
One of the key features of Upadacitinib (Upavoq) is its oral administration and storage at room temperature. Compared with certain injectable therapies that require specific storage conditions, these characteristics offer greater convenience in administration and storage.
In recent years, the development of targeted therapies has expanded the available treatment options for many chronic inflammatory diseases. As a JAK inhibitor, Upadacitinib represents one of the therapeutic options for certain inflammatory and autoimmune conditions within its approved indications.
The selection of this medication, its dosage, and the duration of treatment must be determined by a physician based on the approved indication, the patient’s clinical condition, medical history, and the official product information.
Alborz Zagros, a member of Actoverco Pharmaceutical Group, operates the country’s only pharmaceutical manufacturing facility equipped with OEB (Occupational Exposure Band) Level 5 capabilities. The company specializes in manufacturing medicines containing hazardous active pharmaceutical ingredients (APIs), supporting the treatment of various conditions, including multiple sclerosis and organ transplantation.
